Aesthetics practitioner Dr Catharine Denning and aesthetic nurse prescriber Michelle McLean Park will be hosting ‘Unlocking the science behind Alluzience (botulinum toxin type A) to discuss the first liquid neuromodulator in Europe.
During the webinar, the hosts will discuss the latest clinical studies on the product, with results from practitioners across the UK over the last 12 months, according to Galderma.
Dr Denning commented, “I’m delighted to be speaking on the ‘Unlocking The Science Behind Alluzience’ webinar for the Aesthetics Journal. It will be a great opportunity to share not only my personal insights, but also the extensive science behind such an innovative and valuable product. Alluzience has revolutionised my clinical practice; its innately liquid form saves time and reduces clinical error for me and my practitioners. Alluzience’s fast onset and long duration is very attractive to my busy executive and overseas patients, and having happy patients is the most important thing to me. I’m excited to share more details with you soon.”
The webinar will be held on May 21st 2024 at 7pm.
This is promotional content from Galderma intended for Healthcare Professionals only.
Prescribing information link: Please click here for Alluzience (Botulinum toxin type A) Prescribing Information for the UK
Register for the webinar here
